BioSyent Inc. (CVE:RX – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$14.19 and traded as high as C$14.70. BioSyent shares last traded at C$14.70, with a volume of 3,046 shares changing hands.
BioSyent Trading Up 1.4%
The company has a quick ratio of 6.91, a current ratio of 1.89 and a debt-to-equity ratio of 11.66. The company’s 50-day moving average is C$14.19 and its 200-day moving average is C$14.32. The stock has a market capitalization of C$166.58 million, a price-to-earnings ratio of 18.75 and a beta of 0.99.
Insider Activity
In other news, Director Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of C$14.65, for a total transaction of C$27,600.60. Following the sale, the director owned 37,261 shares of the company’s stock, valued at approximately C$545,873.65. The trade was a 4.81% decrease in their position. In the last three months, insiders have sold 4,358 shares of company stock worth $63,132. 33.65% of the stock is owned by company insiders.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Stories
- Five stocks we like better than BioSyent
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
